Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 CAD | +3.25% | +8.16% | -11.17% |
04-11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
04-11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
Sales 2024 * | 750K 549K | Sales 2025 * | 5.72M 4.19M | Capitalization | 120M 87.74M |
---|---|---|---|---|---|
Net income 2024 * | -35M -25.61M | Net income 2025 * | -40M -29.27M | EV / Sales 2024 * | 160 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 21 x |
P/E ratio 2024 * |
-3.63
x | P/E ratio 2025 * |
-3.69
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.1% |
Latest transcript on Oncolytics Biotech Inc.
1 day | +3.25% | ||
1 week | +8.16% | ||
Current month | +3.92% | ||
1 month | +11.19% | ||
6 months | -28.70% | ||
Current year | -11.17% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Coffey
CEO | Chief Executive Officer | - | 11-05-10 |
Kirk Look
DFI | Director of Finance/CFO | - | 03-03-31 |
Thomas Heineman
CTO | Chief Tech/Sci/R&D Officer | - | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Rigby
BRD | Director/Board Member | 56 | 22-09-06 |
Patricia Andrews
BRD | Director/Board Member | 66 | 01-08 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 15-06-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 1.59 | +3.25% | 25,283 |
24-05-01 | 1.54 | +0.65% | 69,935 |
24-04-30 | 1.53 | +2.00% | 11,088 |
24-04-29 | 1.5 | +2.04% | 31,243 |
24-04-26 | 1.47 | -1.34% | 14,646 |
Delayed Quote Toronto S.E., May 02, 2024 at 03:38 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.17% | 84.41M | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- ONC Stock